Formulation Development
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors
Medigene AG recently announced it has selected its lead candidate for MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma…
Alto Neuroscience Initiates Phase 2 Study of a Novel PDE4 Inhibitor in Cognitive Impairment Associated With Schizophrenia
Alto Neuroscience, Inc. recently announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ALTO-101, a novel PDE4 inhibitor in development…
Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy Designation for NRTX-1001 in Focal Epilepsy
Neurona Therapeutics recently announced the US FDA has granted the company’s lead product candidate, NRTX-1001, the RMAT expedited program designation for drug-resistant mesial temporal lobe…
Macomics & the Institute of Oncology Research Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development
Macomics Ltd recently announced it has entered a scientific collaboration with Prof. Andrea Alimonti at IOR (Institute of Oncology Research), one of Switzerland’s leading research…
Sterling Pharma Solutions Expands Bioanalytical Method Development Capabilities
Sterling Pharma Solutions recently announced it has expanded its bioanalytical services offering at its Deeside, UK, site, which is the company’s dedicated facility for antibody-drug…
WACKER & CordenPharma Enter Pandemic Readiness After Successful Expansion & Qualification
WACKER and CordenPharma recently announced their joint consortium has officially entered the pandemic readiness state as of June 2024. Following a successful expansion and qualification…
Alvotech & Advanz Pharma Sign Commercialization Agreement
Alvotech and Advanz Pharma recently announced they have entered into an exclusive partnership agreement regarding the supply and commercialization of Alvotech’s proposed biosimilar to Eylea…
Altus Formulation & Spektar Join Forces in New Specialty Company Spektus Pharma
Spektar Therapeutics FZCO and Altus Formulation Inc. recently announced the launch of Spektus Pharma Inc. a new Canadian specialty pharma company developing patent-protected value-added medicines…
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
Zentalis Pharmaceuticals, Inc. recently announced the US FDA has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation…
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed With Phase 2 Trial for LSALT Peptide
Arch Biopartners Inc. recently announced the University of Calgary’s Conjoint Health Research Ethics Board (CHREB) has approved the Phase 2 trial for LSALT peptide targeting…
Celonic Inaugurates Next-Gen Biologics Development Center & Pilot Plant
The Celonic Group recently opened its “Next Generation” Biologics Development Center and Pilot Plant in Basel, Switzerland. This laboratory expansion will help pharmaceutical companies develop…
Actylis Announces Appointment of Scott Thomson as Chief Executive Officer
Actylis, a leading global manufacturer and sourcing expert of critical materials and performance ingredients for the life sciences and specialty chemicals markets, today announced the…
Zymeworks Announces FDA Clearance of IND Application for Novel 2+1 T-Cell Targeting Bispecific Antibody For Mesothelin-Expressing Cancers
Zymeworks Inc. recently announced the US FDA has cleared the investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for…
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data
Barinthus Biotherapeutics plc recently announced plans to prioritize its pipeline to focus on the development of VTP-300 in CHB and VTP-1000 in celiac disease. The…
Greenwich LifeSciences Announces $2.5-Million Private Placement
Greenwich LifeSciences, Inc. recently announced it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale…
LIXTE Biotechnology Announces Collaboration on New Colon Cancer Clinical Trial
LIXTE Biotechnology Holdings, Inc. recently announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive…
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for AI-Designed Personalized Cancer Vaccine
Evaxion Biotech A/S recently announced publication of data from its Phase 1 dose escalation study of its lead personalized cancer vaccine candidate, EVX-01, for metastatic…
Grifols’ Biotest Receives FDA Approval for Innovative Immunoglobulin
Grifols recently announced Biotest, a Grifols Group company, has received approval from the US FDA for Yimmugo, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary…
Biosplice Announces Collaboration With Novo Nordisk in Diabetes
Biosplice Therapeutics, Inc. recently entered a collaboration with Novo Nordisk to develop drug candidates for the treatment of diabetes. This agreement builds upon Biosplice’s innovative…
CERo Therapeutics Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound
CERo Therapeutics Holdings, Inc. recently announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236. The completion of multiple manufacturing runs is required…
